Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

Genetic Testing of Noonan Subjects Previously Treated With Norditropin®. An Extension to Trial GHNOO-1658

Phase 3

Completed

Conditions: Genetic Disorder
Noonan Syndrome

Interventions: Drug: somatropin

First Posted Date: 2012-02-09

Last Posted Date: 2023-08-09

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 22

Registration Number: NCT01529944

Somatropin Effect on Linear Growth and Final Height in Subjects With Noonan Syndrome

Phase 3

Completed

Conditions: Genetic Disorder
Noonan Syndrome

Interventions: Drug: somatropin

First Posted Date: 2012-02-09

Last Posted Date: 2017-01-18

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 24

Registration Number: NCT01529840

Locations: 🇸🇪
Novo Nordisk Investigational Site, Göteborg, Sweden

Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Healthy Japanese Subjects

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2
Diabetes

Interventions: Drug: biphasic insulin aspart 50

First Posted Date: 2012-02-07

Last Posted Date: 2017-02-24

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 30

Registration Number: NCT01527630

Locations: 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan

Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2
Diabetes

Interventions: Drug: biphasic insulin aspart 30

First Posted Date: 2012-02-07

Last Posted Date: 2017-02-24

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 25

Registration Number: NCT01527539

Locations: 🇨🇦
Novo Nordisk Investigational Site, Windsor, Canada

Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Healthy Male Subjects

Phase 1

Completed

Conditions: Diabetes
Healthy

Interventions: Drug: biphasic insulin aspart 50

First Posted Date: 2012-02-07

Last Posted Date: 2017-02-24

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 30

Registration Number: NCT01527552

Locations: 🇿🇦
Novo Nordisk Investigational Site, Bloemfontein, South Africa

Bioequivalence of Two Formulations of Biphasic Insulin Aspart 70 in Healthy Subjects

Phase 1

Completed

Conditions: Diabetes
Healthy

Interventions: Drug: biphasic insulin aspart 70

First Posted Date: 2012-02-07

Last Posted Date: 2017-01-06

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 40

Registration Number: NCT01527656

Locations: 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany

Bioequivalence of Two Formulations of Biphasic Insulin Aspart 70 in Healthy Male Subjects

Phase 1

Completed

Conditions: Diabetes
Healthy

Interventions: Drug: biphasic insulin aspart 70

First Posted Date: 2012-02-07

Last Posted Date: 2017-02-24

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 30

Registration Number: NCT01527565

Locations: 🇿🇦
Novo Nordisk Investigational Site, Bloemfontein, South Africa

Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Healthy Subjects

Phase 1

Completed

Conditions: Healthy
Diabetes

Interventions: Drug: biphasic insulin aspart 50

First Posted Date: 2012-02-07

Last Posted Date: 2017-02-24

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 30

Registration Number: NCT01527643

Locations: 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany

Comparison of Single Dose and Steady State Pharmacodynamics of Biphasic Insulin Aspart 30 and 70 in Subjects With Type 1 Diabetes

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1

Interventions: Drug: biphasic insulin aspart 30
Drug: biphasic insulin aspart 70

First Posted Date: 2012-02-06

Last Posted Date: 2017-01-05

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 27

Registration Number: NCT01526941

Locations: 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany

Glycaemic Control of Biphasic Insulin Aspart 70 and 30 in Subjects With Type 2 Diabetes

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 2
Diabetes

Interventions: Drug: biphasic insulin aspart 30
Drug: biphasic insulin aspart 70
Drug: biphasic human insulin 30

First Posted Date: 2012-02-06

Last Posted Date: 2017-01-05

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 31

Registration Number: NCT01526980

Locations: 🇬🇧
Novo Nordisk Investigational Site, Newcastle, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy